Back to News
May 7, 2026 12:00 PM

CMS To Offer Wegovy To Eligible Medicare Patients At $50 Monthly Copay Starting July 2026

The Centers for Medicare & Medicaid Services announced that eligible Medicare beneficiaries living with obesity will gain access to Wegovy (semaglutide) for a $50 monthly copay beginning July 1, 2026, under the new Medicare GLP-1 Bridge program.

The initiative, launched in partnership with Novo Nordisk A/S (NYSE:NVO), will provide nationwide access to all doses and formulations of Wegovy injection and Wegovy pill through the end of 2027.

The program is aimed at expanding access to FDA-approved obesity treatment for millions of Medicare beneficiaries.

Eligible patients will be able to work with healthcare professionals to begin and continue treatment using semaglutide.

Read Also:

GLP-1 Boom Sparks Potential 'Bubble Effect,' Shrinking Competition In Big Pharma, Warns Deloitte: 'The Question Is…'

Program Covers Multiple Wegovy Formulations

According to the announcement on Thursday, the ...